1. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 1487–517.
2. Sims EAH, Calles-Escandon J. Insulin, glucagon, and oral hypoglycemics in the treatment of diabetes mellitus. In: Munson PL, Mueller RA, Breese GR, editors. Principles of pharmacology: basic concepts and clinical applications, rev reprint. New York: Chapman & Hall; 1996. p. 697–723.
3. McEvoy GK, Litvak K, Welsh OH, et al., editors. AHFS drug information. Bethesda: American Society of Health-System Pharmacists; 2000.
4. Klonoff DC. Afrezza inhaled insulin: the fastest-acting FDA-approved insulin on the market has favorable properties. J Diabetes Sci Technol. 2014;8(6):1071–3.
5. Ferner RE, Chaplin S. The relationship between the pharmacokinetic and the pharmacodynamic effects of oral hypoglycemic drugs. Clin Pharmacokinet. 1987;12:397–401.